Burn News and Research

RSS

Safety tips to reduce risk of lead exposure

With more than 2,700 children having elevated blood lead levels in 2009, the Department of Health today reminds parents to test young children for lead exposure, especially during National Lead Poisoning Prevention Week, Oct. 24-30.

25 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

Burn injuries in children show vitamin E depletion in fat tissues

Severe burn injuries in children have been shown to rapidly deplete the levels of vitamin E in their body's adipose, or fat tissues, a new clinical study has found.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

Loyola University Chicago MNSON supports recommendations to advance nursing profession

Loyola University Chicago Marcella Niehoff School of Nursing (MNSON) supports the recommendations recently issued by The Robert Wood Johnson Foundation and the Institute of Medicine to advance the nursing profession in the United States.

20 Oct 2010

Study indicates vitamin D deficiency may increase lung transplant rejection

Vitamin D deficiency is associated with a significant increase in lung transplant rejection, according to research conducted at Loyola University Health System (LUHS). These data were presented Monday at The American Society for Bone and Mineral Research 2010 annual meeting in Toronto, Ontario.

19 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

15 Oct 2010

Food allergies are becoming more common in U.S. children

The scary reality is that food allergies are becoming more and more common in the United States. In the last 10 years there has been an 18 percent increase in children with food allergies. In fact, one in 22 children has a food allergy. That means most likely there is at least one child in each classroom with a food allergy. Halloween parties and trick or treating are just a few of the end of fall activities that can heighten the danger for kids with food allergies.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Researchers from NanoBio Corporation and the University of Michigan Medical School today announced the receipt of a $1.5 million grant from the Department of Defense (DoD) to study the use of nanoemulsion-based therapies for protection against burn and wound infections.

13 Oct 2010

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc. on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

11 Oct 2010

Defense Department's AFIRM to fund Stratatech's Phase IIb clinical trial of StrataGraft tissue

Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that the Defense Department's Armed Forces Institute of Regenerative Medicine will fund the Phase IIb clinical trial of the company's flagship StrataGraft living human skin substitute tissue.

8 Oct 2010

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Hizentra therapy effective for primary immunodeficiency patients

Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).

7 Oct 2010

Burn News and Research

Safety tips to reduce risk of lead exposure

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

Burn injuries in children show vitamin E depletion in fat tissues

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Loyola University Chicago MNSON supports recommendations to advance nursing profession

Study indicates vitamin D deficiency may increase lung transplant rejection

Access receives first MuGard prescriptions and reimbursement

A new therapeutic approach for cancer

Food allergies are becoming more common in U.S. children

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Access highlights clinical benefits of MuGard at ESMO conference

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Defense Department's AFIRM to fund Stratatech's Phase IIb clinical trial of StrataGraft tissue

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

Vivaglobin therapy effective for patients with primary immunodeficiency

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Hizentra therapy effective for primary immunodeficiency patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News